Revealing Clinical Insights on DurAVR THV
In a significant development for the medical device industry, Anteris Technologies Global Corp. (NASDAQ: AVR) has recently announced a pivotal presentation regarding their innovative DurAVR Transcatheter Heart Valve (THV). The anticipated presentation will take place at the renowned TCT® 2025 Conference, which is dedicated to advancing cardiovascular therapies. This session promises to provide valuable insights into the one-year clinical outcomes of patients treated with this advanced heart valve technology.
Overview of the DurAVR System
Innovative Heart Valve Design
The DurAVR Transcatheter Heart Valve is at the forefront of addressing aortic stenosis, a serious condition characterized by the narrowing of the heart's aortic valve. Designed with the input of top cardiologists and cardiac surgeons, the DurAVR THV aims to mimic the natural functioning of a healthy aortic valve. This unique biomimetic design plays a critical role in restoring normal blood flow, which is essential for patients suffering from the debilitating effects of aortic valve disease.
Clinical Evaluation and Positive Outcomes
As the presentation approaches, the excitement builds around the outcomes observed in over 100 patients who have received the DurAVR THV. The statistics and results from these implantations will be a key focus during the presentation, showcasing the effectiveness and safety of the device in clinical settings. Anteris is poised to share compelling data that strengthens the case for the DurAVR THV as a leading option in transcatheter aortic valve replacement (TAVR) procedures.
The Upcoming Presentation at TCT 2025
Scheduled for October 27, the oral presentation will be delivered by Dr. Rishi Puri, who will lead discussions on the one-year clinical outcomes for patients implanted with the DurAVR THV. This session, part of an innovation track dedicated to emerging technologies in TAVR, promises to captivate participants with its insightful findings. Dr. Puri will highlight key outcomes and how the DurAVR THV performs, particularly in patients with small aortic annuli, a demographic that often faces challenges in treatment.
Future Directions: The PARADIGM Trial
Looking ahead, Anteris is actively conducting the global pivotal PARADIGM Trial, which is integral to understanding the broader implications of the DurAVR system in various patient populations. This randomized controlled trial aims to extensively evaluate the safety and effectiveness of the DurAVR THV compared to existing TAVR solutions in the market, further solidifying the company’s position in the competitive landscape of structural heart interventions.
About Anteris Technologies
Anteris Technologies Global Corp. (NASDAQ: AVR) is a key player in the structural heart space, dedicated to revolutionizing treatments for heart disease. With a presence in both Australia and the United States, this science-driven company boasts a dynamic team committed to creating medical devices that truly make a difference for patients. Anteris’ focus on innovation is underscored by its development of the DurAVR THV, which is crafted from their proprietary ADAPT® tissue technology—vetted for safety and effectiveness over years of clinical use.
Contact Information for Inquiries
If you want to learn more about Anteris or the DurAVR THV, the company welcomes inquiries from interested parties. Here are the contact details for investor relations:
For general inquiries, reach out to:
Debbie Ormsby, Anteris Technologies Global Corp.
+61 1300 550 310 | +61 7 3152 3200
Email: investor@anteristech.com
For U.S. investor relations, contact:
Malini Chatterjee, Ph.D., Blueprint Life Science Group
+1 917 330 4269
Email: mchatterjee@bplifescience.com
Frequently Asked Questions
What is the DurAVR THV?
The DurAVR Transcatheter Heart Valve is designed to treat aortic stenosis by mimicking the performance of a healthy aortic valve, enabling normal blood flow.
When will the clinical outcomes be presented?
The presentation will take place on October 27, during the TCT® 2025 Conference.
Who will present the clinical outcomes?
Dr. Rishi Puri will present the findings at the conference.
How many patients have been evaluated with the DurAVR THV?
Over 100 patients have been implanted with the DurAVR THV in clinical settings.
What is the PARADIGM Trial?
The PARADIGM Trial is a randomized controlled trial aimed at evaluating the safety and effectiveness of the DurAVR THV against existing solutions for severe aortic stenosis.
